Thelansis

 Pancreatic ductal adenocarcinoma (PDAC) stands out as a highly aggressive and lethal malignancy primarily due to delayed detection and limited treatment efficacy. Predominantly originating in the exocrine compartment, it constitutes over 90% of pancreatic cancer cases, making it the most prevalent pancreatic neoplasm. Currently, surgical resection combined with adjuvant systemic chemotherapy offers the sole avenue for long-term survival among PDAC patients. However, this opportunity is limited to only a small fraction—approximately 10% to 20%—of individuals diagnosed with localized, resectable disease, while the majority present with metastatic disease, rendering them ineligible for surgery. Moreover, early relapse post-surgery is a common occurrence. For those ineligible for surgery, a multidisciplinary approach involving chemotherapy, radiotherapy, and immunotherapy is recommended for managing unresectable advanced pancreatic cancer. ·        The ...